UnratedDrug recall · FDA · Published September 5, 2025
Endo Everolimus Tablets 5mg Recall: Impurity Risk
Endo recalls Everolimus 5mg tablets due to impurity IP-C failing specifications. Rx-only product with specific lot number. Contact for return instructions.
“Endo Everolimus Tablets 5mg Recall: Impurity Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31802-endo-everolimus-tablets-5mg-recall-impurity-risk. Based on FDA recall #D-0026-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0026-2026%22&limit=1).
The FDA announced on Sept. 5, 2025, that Endo USA, Inc. is recalling Everolimus tablets 5mg due to failed impurity specifications. The voluntary Class III recall affects 1,041 cartons distributed nationwide.
How to tell if you have it
Brand: Endo
Product: Everolimus tablets 5mg, 28 tablets
NDC: 49884-125-91
Lot #: 550172301
Exp. Date: January 2026
The hazard
The recall is due to the product being out of specification for impurity IP-C, constituting failed impurities or degradation specifications.
Context
GovInfoNow's records show Endo USA, Inc. has issued four other recalls since Nov. 18, 2024, including a March 13, 2026, recall for Buprenorphine Injection due to crystallization risk and an Oct. 10, 2025, recall for Everolimus Tablets 10mg over impurity IP-C specifications. Other recent recalls of similar products include Alembic Fesoterodine Tablets Recall (Dec. 16, 2025), Somerset Therapeutics Dexamethasone Injection Recall (Feb. 4, 2026), and Zydus Mirabegron 25mg Tablets Recall (Aug. 5, 2026).
How to tell if you have this one
Check for Everolimus 5mg tablets in cartons with 28 tablets (4 blister strips of 7 tablets each). Look for lot number 550172301 and expiration date January 2026.
Brand
Endo
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Identify the lot number and expiration date on the packaging to confirm if your tablets are affected.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 47 days after the firm started it.
1Firm started the recall
2FDA classified it Class III
3Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0026-2026 (September 5, 2025) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0026-2026 to see it in context.
Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.